一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (315k)  required ID / password
Article in Japanese

Case Report

A case of lung cancer with exacerbated Mycobacterium avium lung disease under pembrolizumab treatment

Taro Hirabayashi  Kei Sonehara  Shuhei Nozawa Yuichi Ikuyama  Masamichi Komatsu  Masayuki Hanaoka 

First Department of Internal Medicine, Shinshu University School of Medicine

ABSTRACT

A 74-year-old man with stage IVB lung adenocarcinoma received combination therapy of cytotoxic anti-cancer agents and pembrolizumab as first-line treatment. Mycobacterium avium had been identified in tracheal secretions acid-fast bacillus culture at the time of the lung cancer diagnosis. After two cycles of combination therapy and 14 cycles of pembrolizumab, infiltration shadows in the lung showed disease exacerbation. The patient discontinued pembrolizumab and multiple antibiotic treatment for M. avium lung disease was administered. After 5 months, the infiltration shadows improved, and the sputum acid-fast bacillus culture became negative. We report the case because the association between immunotherapy and pulmonary nontuberculous mycobacteriosis remains unclear.

KEYWORDS

Lung cancer  Immunotherapy  Pembrolizumab  Pulmonary nontuberculous mycobacteriosis  Mycobacterium avium 

Received 24 Mar 2022 / Accepted 25 May 2022

AJRS, 11(5): 301-304, 2022

Google Scholar